Table 1. Pathological and clinical features of 37 primary DLBCL patients.
| Patients | n | % |
|---|---|---|
| Age (year) | ||
| <60 | 17 | 46 |
| ≥60 | 20 | 54 |
| Laterality | ||
| Left | 10 | 27 |
| Right | 22 | 59 |
| Bilateral | 5 | 14 |
| Stage | ||
| I | 22 | 59 |
| II | 9 | 24 |
| III | 1 | 3 |
| IV | 5 | 14 |
| IPI | ||
| 0-1 | 28 | 76 |
| ≥2 | 9 | 24 |
| Histology* | ||
| GCB | 4 [33] | 12 |
| Non-GCB | 29 [33] | 88 |
| BCL-2+ | 22 [25] | 88 |
| Ki67 | ||
| <50% | 3 [27] | 11 |
| 50%-<90% | 19 [27] | 70 |
| ≥90% | 5 [27] | 19 |
| Radiotherapy | 22 | 59 |
| Contralateral testis alone | 8 | 22 |
| Contralateral testis plus abdominal lymphnodes | 14 | 37 |
| Chemotherapy | ||
| Doxorubicin-contained | 31 | 84 |
| Rituximab-contained | 17 | 46 |
| Etoposide-contained | 7 | 19 |
| CNS prophylaxis | 20 | 54 |
| Intrathecal methotrexate/cytarabine | 16 | 43 |
| Intravenous methotrexate | 4 | 11 |
| Treatment modalities | ||
| Surgery alone | 3 | 8 |
| Chemotherapy alone | 1 | 2 |
| Surgery + radiotherapy | 3 | 8 |
| Surgery + chemotherapy | 11 | 30 |
| Surgery + chemotherapy + radiotherapy | 19 | 52 |
IPI, international prognostic index; BCL-2, b-cell leukemia-2; GCB, grminal center B cell like lymphoma; non-GCB, non-grminal center B cell like lymphoma; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma. *, GCB type was evaluated in 33 patients, BCL-2 was assessed in 25 patients and Ki67 was detected in 27 patients.